Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Murray

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.
Hormones & Cancer|July 16, 2011
Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancerJie Qing Chen, Jennifer Litton, Li Xiao, et al.
Clinical Breast Cancer|April 28, 2015
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast CancerAna M Gonzalez-Angulo, Xiudong Lei, Richardo H Alvarez, et al.
Cancer|March 29, 2014
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancerRashmi K Murthy, Ankur Varma, Priyankana Mishra, et al.
Journal of Virology|September 6, 2005
Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virusJames L Murray, Manos Mavrakis, Natalie J McDonald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistryTakayuki Iwamoto, Daniel Booser, Vicente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancerSharon H Giordano, Daniel J Booser, James L Murray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancerLajos Pusztai, Jim Hou Zhen, Banu Arun, et al.
Plos One|August 23, 2011
Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancerPatricia A Thompson, Abenaa M Brewster, Do Kim-Anh, et al.
Investigational New Drugs|October 13, 2018
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-βClinton Yam, Rashmi K Murthy, Gaiane M Rauch, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.
Hormones & Cancer|July 16, 2011
Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancerJie Qing Chen, Jennifer Litton, Li Xiao, et al.
Clinical Breast Cancer|April 28, 2015
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast CancerAna M Gonzalez-Angulo, Xiudong Lei, Richardo H Alvarez, et al.
Cancer|March 29, 2014
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancerRashmi K Murthy, Ankur Varma, Priyankana Mishra, et al.
Journal of Virology|September 6, 2005
Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virusJames L Murray, Manos Mavrakis, Natalie J McDonald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistryTakayuki Iwamoto, Daniel Booser, Vicente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancerSharon H Giordano, Daniel J Booser, James L Murray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancerLajos Pusztai, Jim Hou Zhen, Banu Arun, et al.
Plos One|August 23, 2011
Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancerPatricia A Thompson, Abenaa M Brewster, Do Kim-Anh, et al.
Investigational New Drugs|October 13, 2018
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-βClinton Yam, Rashmi K Murthy, Gaiane M Rauch, et al.
Pageof 7